Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC-Real World Efficacy

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Meningioma-Brain Crosstalk: A Scoping Review

    Research output: Contribution to journalReviewResearchpeer-review

  3. Pathologic Characteristics of Pregnancy-Related Meningiomas

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Long-Term Follow-Up and Predictors of Functional Outcome after Surgery for Spinal Meningiomas: A Population-Based Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Immune Cell Profiling of Peripheral Blood as Signature for Response During Checkpoint Inhibition Across Cancer Types

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer - Authors' reply

    Research output: Contribution to journalComment/debateResearchpeer-review

  • Antoine Italiano
  • Shivani Nanda
  • Andrew Briggs
  • Jesus Garcia-Foncillas
  • Ulrik Lassen
  • Gilles Vassal
  • Shivaani Kummar
  • Cornelis M van Tilburg
  • David S Hong
  • Theodore W Laetsch
  • Karen Keating
  • John A Reeves
  • Marc Fellous
  • Barrett H Childs
  • Alexander Drilon
  • David M Hyman
View graph of relations

Randomized controlled basket trials investigating drugs targeting a rare molecular alteration are challenging. Using patients as their own control overcomes some of these challenges. Growth modulation index (GMI) is the ratio of progression-free survival (PFS) on the current therapy to time to progression (TTP) on the last prior line of therapy; GMI ≥ 1.33 is considered a threshold of meaningful clinical activity. In a retrospective, exploratory analysis among patients with advanced tropomyosin receptor kinase (TRK) fusion cancer treated with the selective TRK inhibitor larotrectinib who received ≥1 prior line of therapy for locally advanced/metastatic disease, we determined the proportion of patients with GMI ≥ 1.33; patients who had not progressed by data cut-off were censored for PFS. Among 72 eligible patients, median GMI was 2.68 (range 0.01-48.75). Forty-seven patients (65%) had GMI ≥ 1.33; 13/25 patients (52%) with GMI < 1.33 had not yet progressed on larotrectinib. Kaplan-Meier estimates showed a median GMI of 6.46. The probability of attaining GMI ≥ 1.33 was 0.75 (95% confidence interval (CI), 0.65-0.85). Median TTP on previous treatment was 3.0 months (95% CI, 2.6-4.4). Median PFS on larotrectinib was not estimable ((NE); 95% CI, NE; hazard ratio, 0.220 (95% CI, 0.146-0.332)). This analysis suggests larotrectinib improves PFS for patients with TRK fusion cancer compared with prior therapy.

Original languageEnglish
JournalCancers
Volume12
Issue number11
ISSN2072-6694
DOIs
Publication statusPublished - 4 Nov 2020

ID: 61506913